Seattle-based scientists are reporting more encouraging results from treating blood cancer patients with souped-up immune cells.
The trial, part of a larger study by Seattle-based biotechnology Juno Therapeutics, involved about 50 people with three different types of blood cancer. Patients in this type of trial typically have not responded to the usual treatments, and are nearly out of options.
Scientists from Fred Hutchinson Cancer Research Center re-engineered the patients’ immune cells and injected them back into their bodies. Dr. Cameron Turtle of Fred Hutch reported Monday that 91 percent of those with acute lymphoblastic leukemia went into remission.